Hepatitis C virus (HCV) infection is the leading cause of cirrhosis and liver transplantation in the United States. It is difficult to assess the prevalence of HCV infection; the asymptomatic nature of acute infection and early chronic infection leaves many infected individuals undiagnosed. Exposure to infected blood is the primary means for HCV transmission, with intravenous drug use the most common source. Genotype 1 HCV infection accounts for approximately 75% of cases. Because of the asymptomatic and slow course of HCV infection, many physicians and healthcare advocates support routine testing at the primary care level, especially in patients 40 to 65 years of age. Approximately 80% of individuals infected with HCV fail to clear the virus, although this varies considerably based on sex, age at infection, immune status, route of infection, race, alcohol use, and presence of steatosis. Long-term outcomes of chronic HCV infection are cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The current standard of care for patients with chronic HCV infection is combination therapy with subcutaneous injections of peginterferon plus oral ribavirin for 48 weeks. A sustained virologic response (SVR) is also considered a virologic “cure.” There is a trend toward response-guided therapy, in which treatment duration is shortened or lengthened based on viral genotype, patient characteristics, and viral kinetics. The efficacy and tolerability of peginterferon therapy, however, is limited. Approximately 45% of patients infected with HCV genotype 1 achieve an SVR, whereas 65% of those infected with gentoype 2 or 3 do so. Moreover, retreatment or switching to other interferons provides little benefit. Several new therapies for HCV infection are in development. Protease inhibitors are expected to become the new standard of care for nonresponders, with the potential to become a first-line treatment for chronic HCV infection.
(Am J Manag Care. 2011;17:S108-S115)
Hepatitis C virus (HCV) infection is the most common chronic blood-borne infection in the United States, and it is the leading cause of cirrhosis and liver transplantation.1-3 The Centers for Disease Control and Prevention (CDC) estimated that approximately 18,000 new HCV infections occurred in 2008, and that 2.7 to 3.9 million individuals in the United States are living with chronic infection.4 It is difficult to assess the prevalence of HCV infection; the asymptomatic nature of acute infection and early chronic infection leaves many infected individuals undiagnosed.1 Therefore, it is estimated that up to 5 million people in the United States are infected with HCV. In a large screening program conducted in patients from a Veterans Affairs Medical Center (n= 36,422), 5.4% of patients tested positive for HCV antibodies and 4.2% tested positive for HCV ribonucleic acid (RNA).5 In a study designed to assess the prevalence of HCV infection in patients admitted to 2 urban hospitals’ general internal medicine and trauma services (n = 786), 16% of patients tested positive for HCV antibodies.6 Of the 16%, half (8%) had no prior record of a positive test or diagnosis. An estimated 5.6% of all patients had undiagnosed chronic HCV infection.
Approximately 75% to 80% of individuals acutely infected with HCV will progress to chronic infection, and 60% to 70% will develop chronic liver disease.1 An estimated 20% of patients develop cirrhosis 20 to 30 years after infection, making HCV the leading indication for liver transplant in the United States.1 In the United States, chronic HCV is responsible for 8,000 to 12,000 deaths each year.4 Given the mutability and different strains of the virus, individuals can be reinfected or infected with more than 1 viral genotype.1
Transmission and Risk Factors for HCV Infection
Exposure to infected blood is the primary means for HCV transmission.7 The leading source of infection is intravenous (IV) drug users who share needles and other infected items.1 Other sources of transmission include blood or blood component transfusions prior to 1992; transplantation of solid organs from infected donors; birth to an infected mother; multiple sexual partners, particularly men having sex with men; and occasional exposure to blood, as with healthcare workers.8 The Figure depicts the primary sources of infection for individuals with HCV.9
Risk factors for acquiring HCV include injection drug use, sexual or household contact with a person with hepatitis, blood transfusion prior to 1992, receiving clotting factor concentrates prior to 1987, hemodialysis, maternal-infant transmission, needle sticks, intranasal use of cocaine using shared equipment, surgery, and being a healthcare worker who was in contact with human blood.1,10 However, up to 30% of patients with chronic hepatitis have sporadic or community-acquired infection, meaning they do not have any known risk factors or exposure to infected blood.10
Pathogenesis of HCV Infection
Hepatitis C is a small, enveloped, single-stranded RNA virus that was first identified in 1989.10,11 Since then, 6 major genotypes have been identified and at least 50 subtypes. The most common genotypes in the United States are 1a and 1b, which account for approximately 75% of cases; a total of 10% to 20% of patients are infected with genotypes 2 and 3; these genotypes are most likely to respond to treatment.10 HCV infects the host, then uses some form of viral receptor to enter cells, primarily hepatocytes, where it releases its RNA for replication.12 It is able to avoid immune-mediated destruction, even in immunocompetent individuals, despite an aggressive humoral and cellular immune response. Although the specific mechanisms that enable HCV to escape eradication are unknown, the virus’s propensity to mutate is certainly involved.12
Clinical Symptoms and Signs of HCV Infection
HCV infection rarely causes any symptoms in the acute phase. Approximately 20% to 30% of patients develop jaundice or other symptoms such as fever, fatigue, dark urine, clay-colored stool, abdominal pain, anorexia, nausea, vomiting, and arthralgia.1,13
Acute HCV infection is rarely fulminant, and symptoms usually subside in 3 to 12 weeks.11 Serum viral RNA is detectable within 1 to 2 weeks of exposure and RNA levels continue to rise for several weeks. Levels of serum alanine aminotransferase (ALT) also rise within 4 to 12 weeks, indicating liver injury, and then subside.13 Like acute infection, chronic HCV is often asymptomatic in its early stages, with fatigue being the most common complaint.14 Other symptoms are similar to those described for acute HCV. Because of the nonspecific nature, such symptoms are not often attributed to HCV infection unless there is a reason to suspect it. Symptoms may not correlate to serum ALT concentrations or liver histology, although they do tend to become more common and severe as cirrhosis develops.14,15
Screening and Diagnosis
All individuals seen in medical settings should be screened for risky behavior (past or present) that increases risk of HCV infection. Those who meet certain criteria, described in Table 1, should be tested for the virus and, if the results are positive, counseled on how to avoid transmission.7,15,16 Because of the asymptomatic and slow course of HCV infection (described in detail below), many physicians and healthcare advocates support routine testing at the primary care level, especially in patients 40 to 65 years of age.
Current guidelines recommend that patients with suspected acute or chronic HCV infection first be tested for antibodies to HCV (anti-HCV). HCV RNA testing is recommended in those who tested positive for anti-HCV, those in whom antiviral treatment is being considered, and immunocompromised or other patients with unexplained liver disease and a negative anti-HCV test.7,17
The Food and Drug Administration (FDA) has approved 2 enzyme immunoassays (EIA) for HCV testing, both of which have 99% or better specificity for HCV antibodies.7 In June 2010, the FDA approved the first rapid test for HCV infection. The test uses whole venous blood, requires no laboratory processing, and returns results in about 20 minutes. Positive results should be followed up with a confirmatory test using traditional HCV testing methods.18 In addition, an enhanced chemiluminescence immunoassay and recombinant immunoblot assay are available, although the latter is rarely used given the excellent specificity of EIAs.7
Several qualitative and quantitative assays for HCV RNA are also available. The high sensitivity of the real-time polymerase chain reaction (PCR)-based assay has caused qualitative assays to fall out of use. Genotyping can be accomplished once infection is confirmed; it is useful to guide treatment and is recommended in all patients with HCV infection prior to interferon treatment.7
Liver biopsy, considered the “gold standard” for assessing liver disease status, should be reserved for patients with chronic HCV (and only when information about the fibrotic status of the liver is required for treatment decisions). A biopsy is usually not required in patients with HCV genotype 2 or 3, as they are more likely to obtain a sustained virological response (SVR) to treatment.7
The risks associated with liver biopsy, including bleeding, pain, and organ perforation, have led to efforts to identify less invasive options to assess liver status. Biomarker panels, particularly the Original European Liver Fibrosis Panel, and transient elastography are 2 options under investigation.19,20
Natural History of HCV Infection
Approximately 80% of individuals infected with HCV fail to clear the virus, although this varies considerably based on sex, age at infection, immune status, route of infection, race, alcohol use, and presence of steatosis (accumulation of fat in the liver).11,12,21,22
Beyond that, defining the natural history of the disease is challenging. As noted earlier, most patients are asymptomatic during acute infection, thereby making time of infection difficult if not impossible to determine. Second, the slowcourse of HCV infection means that many patients may be infected for decades before they are diagnosed. When such patients are finally diagnosed, the disease has often advanced to cirrhosis, decompensation, or hepatocellular carcinoma (HCC).23 Moreover, it is unclear if progression of HCV infection is linear and to what degree the mode of transmission (eg, IV drug use) influences clinical sequelae.11,12,23,24
Long-term outcomes of chronic HCV infection are cirrhosis, end-stage liver disease, and HCC. The risk of developing cirrhosis over 30 years ranges from 5% to 25%, although patients who were infected as children and women infected in their 20s are less likely to develop cirrhosis. In addition, patients with persistent ALT elevations but no fibrosis and minimal necroinflammatory changes are likely to have a very slow progression to cirrhosis.3,12 Individuals who are infected at an older age, are immunocompromised (ie, have human immunodeficiency virus infection [HIV]), are obese, or consume more than 50 g of alcohol a day are more likely to develop cirrhosis.
One review of 111 studies on the natural history of HCV infection estimated that approximately 16% of patients develop cirrhosis 20 years after infection (95% confidence interval: 14%-90%).25 Another meta-analysis of data on the natural history of HCV and HIV coinfection determined that 21% of patients developed cirrhosis after 20 years and 49% after 30 years, with a longer duration of HCV infection associated with a slower progression of fibrosis. Compared with patients with HCV infection, those with HCV and HIV infection had a higher rate of cirrhosis regardless of highly active antiretroviral therapy.26 One-third of patients who develop cirrhosis will progress to hepatic decomposition over 10 years, while 1% to 3% each year will develop HCC.27
Mortality due to HCV infection varies. Patients followed for 25 years after a posttransfusion infection demonstrated no difference in all-cause mortality from a control group, although patients with HCV infection had an increased rate of liver mortality (4.1% vs 1.3%, respectively). In addition, 17% had or were suspected to have cirrhosis.28 The most common extrahepatic manifestation of HCV infection is HCV-related cryoglobulinemia (presence of abnormal proteins in the blood). Although it occurs in less than 1% of patients, up to half of these patients have clinical manifestations, including low levels of serum cryoglobulins, rheumatoid factor, and immunologic markers of vasculitis. Untreated cryoglobulinemia can lead to progressive renal disease and severe vasculitic complications. Thus, its presence is an indication for HCV treatment.7,11,29,30
Management of HCV Infection
The goal of treatment for chronic HCV is to prevent complications and HCV-related mortality. However, the slow course of the disease makes it difficult to determine if treatment prevents liver-related complications. In the short term, a reduction in serum ALT levels, the absence of HCV RNA, and improvement in necroinflammatory score with no worsening in fibrosis score may be used to evaluate therapy.7
Over the long term, however, viral kinetics are used to evaluate therapy. Virologic responses are explained in Table 2. The most important is an SVR, also considered a virologic “cure.”7
Current Treatment Options
The current standard of care for patients with chronic HCV infection is combination therapy with subcutaneous injections of peginterferon plus oral ribavirin (RBV) for 48 weeks.3,31,32 Recommended dosages are peginterferon α-2a at 180 μg per week, and RBV at a weight-based dosage of 1000 mg for those 75 kg or less in weight and 1200 mg for those weighing more than 75 kg. The dosage for peginterferon α-2b is 1.5 μg/kg per week, with a weight-based dosage of RBV at 800 mg for those less than 65 kg, 1000 mg for those more than 65 kg but less than 85 kg, 1200 mg for those between 85 kg and 105 kg, and 1400 mg for those more than 105 kg.7
Although each agent carries the risk of serious side effects, risks are greater with combined therapy. Neutropenia and anemia are particularly concerning. In 2 phase 3 trials with peginterferon and RBV, approximately 20% of patients experienced neutropenia or anemia requiring dose reductions or discontinuation.31,33
Common side effects of influenza-like symptoms, depression, headache, and fever, coupled with neuropsychiatric conditions such as depression, irritability, and insomnia, can lead to dosage reduction and discontinuation.31,33 Such adverse events, as well as individual patient characteristics, lead to lower rates of adherence (and therefore treatment efficacy) over time.34 One study found that patients were willing to accept a lower viral response in exchange for fewer adverse effects, particularly depression and flu-like symptoms. The study, which provided patients with a choice-format conjoint survey, identified an 80% adherence to therapy with no flu-like symptoms, and an adherence rate of just 66.4% when flu-like symptoms were expected for 4 days.34
Because the adverse effects of combination therapy tend to increase over time, the shortest possible treatment time is recommended. Thus, guidelines call for discontinuing therapy in patients who do not achieve an early virologic response (EVR) at 12 weeks and retesting patients who do not achieve HCV RNA negativity at 24 weeks.32
There is a trend toward response-guided therapy, in which treatment duration is shortened or lengthened based on viral genotype, patient characteristics, and viral kinetics. For instance, patients with HCV genotype 2 or 3 who demonstrate a rapid virologic response (RVR) at week 4 are significantly more likely to achieve an SVR following a 16-week course of treatment. This shorter regimen is most effective in patients up to 45 years of age with low baseline HCV RNA levels (<400,000 IU/ml) and minimal fibrosis.35 Conversely, treatment duration may be extended to 72 weeks in patients with genotype 1 HCV infection, who may experience a delayed virus clearance.7,36 After patients achieve SVR, those with cirrhosis should be regularly monitored for the development of HCC.7
Decision to Treat
Although all patients with HCV infection are candidates for treatment, the indolent course of the disease, social history of some patients, and adverse effects and cost of therapy require that clinicians and patients determine when and if it is appropriate to begin therapy. The economic considerations of treatment initiation are discussed in the accompanying articles in this supplement; the focus of this article is the clinical implications of those decisions.
The 2002 National Institutes of Health Consensus Statement on the Management of Hepatitis C recommends treatment in patients with histological evidence of progressive disease. Such patients have detectable HCV RNA levels higher than 50 IU/mL, liver biopsy results demonstrating portal or bridging fibrosis, and “at least” moderate inflammation and necrosis. Most patients will also have persistently elevated ALT values.3 The panel also recommended that patients with less severe histological disease be managed on an individual basis, and that patient selection for treatment not be based on the presence or absence of symptoms, the mode of acquisition, the genotype of HCV RNA, or serum HCV RNA levels. Specific recommendations are highlighted in Table 3.3
Although liver transplantation is typically recommended in patients with cirrhosis, a recent analysis of 568 patients at 26 centers with clinically compensated HCV-related cirrhosis undergoing treatment with peginterferon-α/RBV reported an SVR in treatment-naïve patients of 30.7% after a median follow-up of 35 months.37 Predictors of SVR were non-genotype 1, low baseline viral load, low serum gammaglutamyl transpeptidase, no signs of portal hypertension (via ultrasonography), and an RVR at week 4. Patients who achieved an SVR had an event-free survival rate at 5 years of 98% versus 59% in nonresponders (P <.001).
Consensus interferon (CIFN) is also indicated for the treatment of chronic HCV in adults with compensated liver disease and, in combination with RBV, for patients with HCV infection who need retreatment.38 It was approved for that indication prior to the approval of the current standard of treatment, however, and has not been evaluated in treatment-naïve patients. Today, CIFN is primarily used for patients who have failed peginterferon/RBV therapy and can tolerate interferon.39
Nonresponders to Interferon Therapy
The efficacy and tolerability of peginterferon therapy is limited. Approximately 45% of patients infected with HCV genotype 1 achieve an SVR, whereas 65% of those infected with gentoype 2 or 3 do so.31 Retreatment or switching to other interferons provides little benefit.40,41
Unfortunately, long-term treatment is not associated with additional benefits. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial was designed to evaluate long-term maintenance treatment on the progression to cirrhosis, but reported no benefits.42 Long-term treatment (median, 6.1 years) was not associated with a lower incidence of HCC.43 It did, however, demonstrate a significant reduction in clinical outcomes (including Child-Turcotte-Pugh score, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, variceal hemorrhage, hepatocellular carcinoma, and mortality) in patients who reached viral RNA suppression of at least 4 log10. The number of patients who reached this threshold was low (178/763, or 23%), however, and only 30 patients had a sustained virologic reduction.44
Another option in nonresponders is extending peginterferon therapy to 72 weeks. In the REPEAT (Retreatment with Pegasys in patients Not Responding to Peg-Intron Therapy) trial, which included 950 nonresponders, patients who received 72 weeks of combination therapy had an SVR rate of 16% compared with 8% of those who received the standard 48 weeks of treatment (relative risk, 2.00; confidence interval, 1.32 to 3.02; P <.001). The likelihood of SVR could be determined based on viral response at week 12.45 Based on the trial results, current guidelines call for retreatment with peginterferon/RBV in nonresponders or those who relapse and were previously treated with nonpeginterferon with or without RBV, or with peginterferon monotherapy, particularly in those with bridging fibrosis or cirrhosis.7
Nonresponders may also be treated with CIFN, which received FDA approval in June 2010 for retreatment of nonresponders based on results from the DIRECT (Daily-DoseConsensus Interferon and Ribavirin: Efficacy of Combined Therapy) trial. In this open-label trial, 487 nonresponders were randomized to CIFN 9 μg/day monotherapy; 15 μg/day oral RBV based on body weight; or to a control, no treatment group. Approximately 60% of patients had documented advanced fibrosis at baseline liver biopsy.46
Overall, SVR rates were 6.9% in the 9-μg group and 10.7% in the 1-μg group, with higher SVR rates in patients with less disease progression and greater viral load decline. Relapse rates were 52% in the 9-μg group and 42% in the 15-μg group.46 Treatment was well tolerated, with 83.6% of patients in the 9-μg group and 71.7% of patients in the 15-μg group receiving at least 80% of the CIFN dose. Treatment failure was the most common reason for early termination.
Potential Impact of Future Therapies
The article in this supplement by Poordad et al47 provides a comprehensive overview of the current environment for novel therapies, including the results of late-stage clinical trials. There is significant excitement in the field about these new options, particularly the protease inhibitors. A survey of 78 US physicians who treat at least 10 patients with chronic HCV infection each month found that one-third were “warehousing” their patients, or delaying therapy, in anticipation of new therapies.48
The expectation is that the protease inhibitors will become the new standard of care for nonresponders, with the potential to become a first-line treatment for chronic HCV infection. Initially, it is expected that these direct-acting antivirals will be used as add-on therapy to current peginterferon/RBV regimens at the current treatment duration of 48 weeks or 24 weeks with significantly improved efficacy.49
However, these options will not be applicable to all patients with HCV infection, particularly those who have HCV genotype 2 or 3, and those who are intolerant to or have contraindications to peginterferon or RBV, leaving a continuing unmet need for effective therapies for these patients with chronic HCV infection.49
Acknowledgment: Editorial support for this manuscript was provided by Debra Gordon, MS, of GordonSquared, Inc.
Author Affiliation: Schiff Liver Institute/Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, FL.
Funding Source: Financial support for this work was provided by Merck & Co, Inc.
Author Disclosure: Dr Schiff reports being a member of the scientific advisory board for Bristol-Myers Squibb, Gilead, GlobeImmune, Johnson & Johnson, Merck, Roche Molecular, Schering-Plough, and Vertex. He also reports being a member of the data safety monitoring board for Daiichi-Sankyo, Johnson & Johnson, Pfizer, Salix Pharmaceuticals, and sanofiaventis. Dr Schiff has received grants from Abbott, Anadys, Bristol-Myers Squibb, Gilead, GlobeImmune, Medtronic, Merck, Roche Diagnostics, Roche Molecular, Salix Pharmaceuticals, sanofi-aventis, Schering-Plough, SciClone Pharmaceuticals, and Vertex.
Authorship Information: Concept and design; drafting of the manuscript; and critical revision of the manuscript for important intellectual content.
Address correspondence to: Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, Schiff Liver Institute/Center for Liver Diseases, University of Miami Miller School of Medicine, 1500 NW 12 Ave, Jackson Medical Tower E-1101, Miami, FL, 33136. E-mail: firstname.lastname@example.org.
1. Centers for Disease Control and Prevention. Hepatitis C FAQs for Health Professionals. Last updated: December 17, 2010. Available at: http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm#. Accessed February 8, 2011.
2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714.
3. National Institutes of Health. NIH Consensus Statement on Management of Hepatitis C: 2002. http://www.nlm.nih.gov/archive//20061214/pubs/cbm/hepatitis_c_2002_2.html. Accessed March 16, 2011.
4. Centers for Disease Control and Prevention. Disease Burden from Viral Hepatitis A, B, and C in the United States. Last updated: November 15, 2010. Available at: http://www.cdc.gov/hepatitis/HCV/StatisticsHCV.htm. Accessed February 8, 2011.
5. Groom H, Dieperink E, Nelson DB, et al. Outcomes of a Hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol. 2008;42(1):97-106.
6. Brady KA, Weiner M, Turner BJ. Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals. J Infect. 2009;59(1):62-69.
7. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4):1335-1374.
8. Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36(5 suppl 1):S93-S98.
9. Centers for Disease Control and Prevention. National Hepatitis C Prevention Strategy 2001. Available at: http://www.cdc.gov/hepatitis/HCV/Strategy/NatHepCPrevStrategy.htm. Accessed February 14, 2011.
10. National Institute of Diabetes and Digestive and Kidney Diseases. Hepatitis C: Current Disease Management 2010. Available at: http://digestive.niddk.nih.gov/ddiseases/pubs/chronichepc/index.htm. Accessed March 16, 2011.
11. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36(5 suppl 1):S21-S29.
12. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296-305.
13. McHutchison JG. Understanding hepatitis C. Am J Manag Care. 2004;10(2 suppl):S21-S29.
14. Merican I, Sherlock S, McIntyre N, et al. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med. 1993;86(2):119-125.
15. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med. 1995;123(5):330-337.
16. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47 (RR-19):1-39.
17. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003; 52(RR-3):1-13, 15; quiz CE11-14.
18. Food and Drug Administration. FDA approves rapid test for antibodies to hepatitis C virus. News & Events. 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm217318.htm. Accessed February 9, 2011.
19. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47(2):455-460.
20. Sagir A, Erhardt A, Schmitt M, et al. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology. 2008;47(2):592-595.
21. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340(16):1228-1233.
22. Wiese M, Grungreiff K, Guthoff W, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. J Hepatol. 2005;43(4):590-598.
23. Kanwal F, Bacon BR. Does treatment alter the natural history of patients with chronic hepatitis C virus infection. In: Shiffman ML, eds., Chronic hepatitis C virus: lessons from the past, promise for the future. Springer, 2011 (in press).
24. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 suppl 1):S35-S46.
25. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418-431.
26. Thein HH, Yi Q, Dore GJ, et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979-1991.
27. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463-472.
28. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology. 2001;33(2):455-463.
29. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21): 1490-1495.
30. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med. 1992;117(7):573-577.
31. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.
32. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-355.
33. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-965.
34. Brett Hauber A, Mohamed AF, Beam C, et al. Patient preferences and assessment of likely adherence to hepatitis C virus treatment. J Viral Hepat. [published online ahead of print June 22, 2010].
35. Zeuzem S, Rizzetto M, Ferenci P, et al. Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response. Antivir Ther. 2009;14(2):143-154.
36. Tsubota A, Fujise K, Namiki Y, et al. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol. 2011;17(4):419-432.
37. Fernandez-Rodriguez CM, Alonso S, Martinez SM, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105(10):2164-2172; quiz 2173.
38. Infergen [prescribing information]. Biberach, Germany: Boehringer Ingelheim Pharma and Warrendale, Pa: Three Rivers Pharmaceutical, LLC; 2010.
39. Alavian SM, Behnava B, Tabatabaei SV. Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2010;66(11):1071-1079.
40. Cheruvattath R, Rosati MJ, Gautam M, et al. Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci. 2007;52(3):732-736.
41. Cornberg M, Hadem J, Herrmann E, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol. 2006;44(2):291-301.
42. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359(23):2429-2441.
43. Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011;140(3):840-849.
44. Shiffman ML, Morishima C, Dienstag JL, et al. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology. 2009; 137(6):1986-1994.
45. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009;150(8): 528-540.
46. Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009;49(6):1838-1846.
47. Poordad F, Khungar V. Emerging therapeutic options in hepatitis C virus infection. Am J Manag Care. 2011;17:S123-S130.
48. Hoggatt J. Survey: anticipation high for telaprevir and boceprevir. inThought Research. 2010. Available at: www.inthought.com/resources/HepCSurvey.WK.25Oct.pdf. Accessed January 24, 2011.
49. Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int. 2011;31(suppl 1):62-67.